Drugs / JS111
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06940401 | Apr 2025 → Jul 2028 expected | non-small cell lung carcinoma | Suzhou Junjing BioSciences Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04993391 | Jul 2021 → Jun 2024 | lung cancer | Suzhou Junjing BioSciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07518160 | Apr 2026 → Apr 2028 expected | lung cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07714304 | Jul → Nov 2026 expected | — | Huan Zhou | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07518160 ↗ |
| Known as | AP-L1898 | “This is a Phase II clinical study evaluating JS111 capsules (AP-L1898) as monotherapy in patients with advanced NSCLC harboring EGFR mutations.” NCT06940401 ↗2“JS111 capsules (AP-L1898) : JS111 160 mg orally once daily” NCT07518160 ↗ “JS111 capsules (AP-L1898)” NCT07714304 ↗ |
| Known as | JS111 capsules | “JS111 capsules (AP-L1898) : JS111 160 mg orally once daily” NCT07518160 ↗ |
| Route | Oral | “receive oral JS111 capsules once daily” NCT06940401 ↗ |